A combined application of cisplatin with biochemical modulators of p53-mediated DNA damage response or MMR function frequently led to a favorable response in colon cancer cell lines and pre-clinical tumor models of colorectal cancer. The gene discussed is TP53; the disease is malignant colon neoplasm.